Treatment of Premature Ovarian Insufficiency with Hormone Replacement Therapy
Core Treatment Approach
- The American College of Obstetricians and Gynecologists recommends hormone replacement therapy with transdermal 17β-estradiol (50-100 μg daily) combined with cyclic micronized progesterone (100-200 mg/day for 12-14 days per month) to prevent cardiovascular disease, osteoporosis, and premature mortality in women with premature ovarian insufficiency 1
- Transdermal 17β-estradiol is the preferred route of administration, providing physiological serum concentrations and a superior cardiovascular and metabolic profile compared to oral conjugated estrogens 2, 3
- Micronized natural progesterone (100-200 mg/day orally) for 12-14 days per month is the recommended progestogen choice for women with an intact uterus 2, 3
Duration and Monitoring Strategy
- The European Society of Human Reproduction and Embryology recommends continuing hormone replacement therapy at minimum until age 50-51 years to control future cardiovascular disease risk and prevent osteoporosis 1, 3
- Annual clinical review focusing on compliance, blood pressure, weight, and smoking status is recommended 1
- Baseline bone mineral density measurement at diagnosis is recommended, especially with additional risk factors 5, 6
Critical Considerations for Long-Term Health
- Women with premature ovarian insufficiency face significantly increased cardiovascular disease risk due to prolonged estrogen deficiency, and hormone replacement therapy with early initiation is strongly recommended to control future cardiovascular risk 1, 6
- Adequate systemic estrogen replacement is the primary intervention for bone protection, and declining bone mineral density should prompt review of estrogen adequacy 5, 6
Absolute Contraindications
- The American College of Obstetricians and Gynecologists recommends avoiding hormone replacement therapy in women with a personal history of breast cancer or active venous thromboembolism 3